Overview

Study to Evaluate the Antiviral Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Participants With Chronic Hepatitis B Infection

Status:
Active, not recruiting

Trial end date:
2027-07-01

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to evaluate the antiviral efficacy of tenofovir disoproxil fumarate (tenofovir DF; TDF) versus placebo in pediatric population (aged 2 to < 12 years at the time of enrollment) with chronic hepatitis B (CHB) infection.

Phase:

Phase 3

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Tenofovir